Early Phase Development of Centrally-Acting Drugs

September 14, 2016

Café ArtScience (in the Private Dining Room)
650 E Kendall St, Cambridge, MA 02142, United States

857 999-2193

cafeartscience.com

Speaker Bios Abstracts Agenda

Altasciences Clinical Research and Cambridge Cognition are pleased to invite you to this complimentary scientific symposium which is designed for members of the pharmaceutical and biotech communities to discuss and share ideas on early phase development of centrally acting drugs.

Join us as industry experts share in-depth knowledge on the following topics:

If you have any questions about this symposium or would like information on obtaining a certificate of completion, contact Sarah Stapleton at sstapleton@altasciences.com or call 913 696-1601.

Agenda

September 14, 2016

  • Cocktails and hors d'oeuvres

  • Introduction

    Graham Wood, PhD, Executive Vice President, Phase I Clinical Development, Altasciences Clinical Research

  • Challenges in Early Phase CNS Clinical Drug Development

    Mike Detke, MD, Consultant and Contract CMO for Embera Neurotherapeutics

  • Adaptive Approaches to Optimize Early Phase Clinical Trials

    Amanda J. Moore, MSHS, Associate Director, Clinical Operations and Development, Sage Therapeutics

  • Assessing Cognitive Function for Safety and Efficacy in Drug Development

    Kenton H. Zavitz, PhD, Director of Clinical Affairs, Cambridge Cognition Ltd

    Graham Wood, PhD, Executive Vice President, Phase I Clinical Development, Altasciences Clinical Research

  • Cocktails and hors d'oeuvres